comparemela.com

Latest Breaking News On - Navrogen - Page 1 : comparemela.com

Navrogen Announces Publication of NAV-001 Antibody-Drug Conjugate Development and Efficacy in Humoral Immunosuppressed Cancers

/PRNewswire/ Navrogen, Inc., a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, announces today a.

Nicholas nicolaidesSteven kyriakosNavrogen incNavrogen incorporatedHumoral immunology oncologyHumoral immuno oncologyChief executiveHealth care amp hospitalsMedical pharmaceuticalsPublishing amp information servicesClinical trials amp medical discoveries

Navrogen Presents Preclinical Data on NAV-001 Antibody-Drug Conjugate and NAV-003 Bispecific Programs at the 2023 American Association for Cancer Research Annual Meeting

/PRNewswire/ Navrogen, Inc., a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, will be presenting new.

United statesSteven kyriakosLuigi grassoNicholas nicolaidesNavrogen incorporatedPrnewswire navrogen incAmerican association for cancer researchCancer researchHumoral immuno oncologyChief scientificChief executive officer

Navrogen Enters into CRADA with The U S National Cancer Institute for the Clinical Development of NAV-001, an Anti-Mesothelin Antibody-Drug Conjugate

/PRNewswire/ Navrogen, Inc. announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with researchers at the U.S..

United statesIra pastanNicholas nicolaidesSteven kyriakosLuigi grassoRaffit hassanDevelopment agreementUs national cancer instituteNavrogen incorporatedLaboratory of molecular biologyGi malignancies branchNavrogen incNational institutes of healthCancer research laboratory of molecular biologyCooperative researchCancer institute

Navrogen Presents Preclinical Data on Its NAV-001 Antibody-Drug Conjugate Program at the 12th World ADC Conference in London

/PRNewswire/ Navrogen, Inc., a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, will be presenting new.

United kingdomCity ofNavrogen incHumoral immuno oncology

Navrogen Announces Publication of Its Block-Removed Immunoglobulin Technology (BRITE) to Optimize Rituximab Activity in Humoral Immunosuppressed Cancers

/PRNewswire/ Navrogen, Inc., a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, announced today the.

Nicholas nicolaidesLuigi grassoSteve kyriakosImmunoglobulin technologyNavrogen incorporatedNavrogen incRemoved immunoglobulin technologyOncology lettersChief scientific officerHumoral immuno oncology

vimarsana © 2020. All Rights Reserved.